AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33369937 — intervention group
Group type: EXPERIMENTAL
Intervention: NOV03 twice daily (BID)
Number of subjects: 336
Study 33369937 — intervention group
Group type: COMPARATOR
Intervention: Saline BID
Number of subjects: 336
Study 33369937 — intervention group
Group type: COMPARATOR
Intervention: Saline QID
Number of subjects: 336
Study 34369566 — intervention group
Group type: EXPERIMENTAL
Intervention: Light force (300 g)
Number of subjects: 40
Study 34369566 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy force (500 g)
Number of subjects: 40
Study 32916236 — intervention group
Group type: EXPERIMENTAL
Intervention: Photon radiation with chemotherapy
Number of subjects: 178
Study 32916236 — intervention group
Group type: COMPARATOR
Intervention: Proton radiation with chemotherapy
Number of subjects: 178
Study 32916236 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 178
Study 33122694 — intervention group
Group type: EXPERIMENTAL
Intervention: M. officinalis extract containing 500 mg of rosmarinic acid (RA) daily
Number of subjects: 23
Study 33122694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 35102808 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training (40-60% heart rate reserve) and self-management education for 30 minutes, three times a week for 8 weeks
Number of subjects: 119
Study 35102808 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training and self-management education
Number of subjects: 119
Study 36202695 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable hospice
Number of subjects: 24342
Study 36202695 — intervention group
Group type: EXPERIMENTAL
Intervention: SMSCS only
Number of subjects: 24342
Study 36202695 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing intensity
Number of subjects: 24342
Study 36202695 — intervention group
Group type: EXPERIMENTAL
Intervention: CDT or concurrent care
Number of subjects: 24342
Study 36202695 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing intensity
Number of subjects: 24342
Study 36202695 — intervention group
Group type: COMPARATOR
Intervention: Higher healthcare referral region hospice rates
Number of subjects: 24342
Study 36202695 — intervention group
Group type: COMPARATOR
Intervention: Black, non-Hispanic decedents
Number of subjects: 24342
Study 34058616 — intervention group
Group type: EXPERIMENTAL
Intervention: Active range of motion (AROM)
Number of subjects: 164
Study 34058616 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotator cuff function
Number of subjects: 164
Study 34058616 — intervention group
Group type: EXPERIMENTAL
Intervention: Scapular kinematics
Number of subjects: 164
Study 34058616 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical presentation
Number of subjects: 164
Study 34058616 — intervention group
Group type: EXPERIMENTAL
Intervention: Associations between clinical presentation and daily life impact
Number of subjects: 164
Study 32066505 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient balloon catheter induction
Number of subjects: 1552
Study 32066505 — intervention group
Group type: COMPARATOR
Intervention: In-hospital prostaglandin induction
Number of subjects: 1552
Study 34747997 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive messages three times a week for 4 weeks
Number of subjects: 375
Study 34747997 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized, but not interactive messaging
Number of subjects: 375
Study 34747997 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized and interactive messages three times a week for 2 weeks; then daily for 2 weeks
Number of subjects: 375
Study 34747997 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-way interactive messages
Number of subjects: 375
Study 34747997 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant or decreasing message frequency
Number of subjects: 375
Study 35246089 — intervention group
Group type: EXPERIMENTAL
Intervention: HAP‐peptide suspension with NaOCl pre‐treatment (6.25 wt% HAP and 5 ml P11‐4 peptide, NaOCl 3%)
Number of subjects: 52
Study 35246089 — intervention group
Group type: EXPERIMENTAL
Intervention: HAP (6.25 wt%)
Number of subjects: 52
Study 35246089 — intervention group
Group type: EXPERIMENTAL
Intervention: P11‐4 peptide (5 ml)
Number of subjects: 52
Study 35246089 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOCl (3%)
Number of subjects: 52
Study 35246089 — intervention group
Group type: COMPARATOR
Intervention: Water (control group)
Number of subjects: 52
Study 33165879 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg of lidocaine
Number of subjects: 90
Study 33165879 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg of lidocaine
Number of subjects: 90
Study 33165879 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 90
Study 35251574 — intervention group
Group type: EXPERIMENTAL
Intervention: HE‐LSTM model intervention
Number of subjects: 76
Study 35251574 — intervention group
Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 76
Study 34269480 — intervention group
Group type: EXPERIMENTAL
Intervention: LOVED program
Number of subjects: 48
Study 33144344 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Number of subjects: 0
Study 33144344 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35210504 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (MG)
Number of subjects: 40
Study 35210504 — intervention group
Group type: COMPARATOR
Intervention: Standard care (CG)
Number of subjects: 40
Study 32722609 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation
Number of subjects: 90
Study 32722609 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation
Number of subjects: 90
Study 32722609 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 90
Study 36414775 — intervention group
Group type: EXPERIMENTAL
Intervention: CM for PrEP/ART adherence
Number of subjects: 19
Study 36414775 — intervention group
Group type: COMPARATOR
Intervention: CM for MA abstinence
Number of subjects: 19
Study 34444590 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature video
Number of subjects: 506
Study 34444590 — intervention group
Group type: COMPARATOR
Intervention: Built video
Number of subjects: 506
Study 34578868 — intervention group
Group type: EXPERIMENTAL
Intervention: DIANA-5 dietary intervention based on Mediterranean diet and macrobiotic principles
Number of subjects: 1344
Study 34578868 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased recommended foods consumption
Number of subjects: 1344
Study 34578868 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced discouraged foods consumption
Number of subjects: 1344
Study 34578868 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher category of dietary change
Number of subjects: 1344
Study 34578868 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1344
Study 33017219 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothyroidism group
Number of subjects: 61
Study 33017219 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study 33017219 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 61
Study 32528650 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol + Promethazine + Chlorpromazine (HPC)
Number of subjects: 0
Study 32528650 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol + Promethazine (HP)
Number of subjects: 0
Study 35038429 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugemalimab 1200 mg intravenously every 3 weeks for up to 24 months
Number of subjects: 381
Study 35038429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381
Study 35038429 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugemalimab
Number of subjects: 381
Study 32223645 — intervention group
Group type: EXPERIMENTAL
Intervention: Biceps tenodesis
Number of subjects: 114
Study 32223645 — intervention group
Group type: COMPARATOR
Intervention: Biceps tenotomy
Number of subjects: 114
Study 36120830 — intervention group
Group type: EXPERIMENTAL
Intervention: Patisiran
Number of subjects: 225
Study 36120830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 35636727 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 1767
Study 35636727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1767
Study 35636727 — intervention group
Group type: EXPERIMENTAL
Intervention: CV hospitalization
Number of subjects: 1767
Study 35636727 — intervention group
Group type: EXPERIMENTAL
Intervention: non-CV hospitalization
Number of subjects: 1767
Study 35636727 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent hospitalization for CV reasons
Number of subjects: 1767
Study 35636727 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent hospitalization for non-CV reasons
Number of subjects: 1767
Study 35636727 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent hospitalization for both CV and non-CV reasons
Number of subjects: 1767
Study 33677616 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 h HDMTX infusion (12 g/m2)
Number of subjects: 12
Study 33677616 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 h HDMTX infusion (12 g/m2)
Number of subjects: 12
Study 33677616 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 4 h and 12 h infusions
Number of subjects: 12
Study 33196744 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tissue stabilized guided subcision, microfocused ultrasound, and calcium hydroxylapatite injections
Number of subjects: 61
Study 33196744 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant microfocused ultrasound and calcium hydroxylapatite injections followed by tissue stabilized guided subcision
Number of subjects: 61
Study 35237030 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical Bone Trajectory (CBT) screw fixation
Number of subjects: 124
Study 35237030 — intervention group
Group type: COMPARATOR
Intervention: Traditional Pedicle Screw (PS) fixation
Number of subjects: 124
Study 34370833 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D simulation
Number of subjects: 117
Study 34370833 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D photographs
Number of subjects: 117
Study 34370833 — intervention group
Group type: COMPARATOR
Intervention: Standard care (verbal description alone)
Number of subjects: 117
Study 33730398 — intervention group
Group type: EXPERIMENTAL
Intervention: IAC + RT (4 IAC bouts followed by 3 sets of 12 repetitions of 3 lower-limb free-weight exercises)
Number of subjects: 66
Study 33730398 — intervention group
Group type: EXPERIMENTAL
Intervention: IAC + RT
Number of subjects: 66
Study 33730398 — intervention group
Group type: COMPARATOR
Intervention: IAC + IAC (4 + 1 bouts of 4 min at 90% of HRMAX of intense aerobic cycling)
Number of subjects: 66
Study 33730398 — intervention group
Group type: COMPARATOR
Intervention: IAC + IAC
Number of subjects: 66
Study 32603006 — intervention group
Group type: EXPERIMENTAL
Intervention: 1064-nm neodymium-doped yttrium aluminum garnet picosecond laser using a diffractive optical element (P-DOE)
Number of subjects: 25
Study 32603006 — intervention group
Group type: COMPARATOR
Intervention: non-ablative fractional laser (NAFL)
Number of subjects: 25
Study 32603006 — intervention group
Group type: EXPERIMENTAL
Intervention: P-DOE
Number of subjects: 25
Study 34378238 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus + tripterygium glycosides
Number of subjects: 279
Study 34378238 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 279
Study 34378238 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard therapy)
Number of subjects: 279
Study 32066380 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS) supported employment
Number of subjects: 119
Study 32066380 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual vocational rehabilitation (TAU‐VR)
Number of subjects: 119
Study 35134906 — intervention group
Group type: EXPERIMENTAL
Intervention: Teen Council peer education program
Number of subjects: 0
Study 35134906 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 34318912 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat therapy for 25 minutes, two times (at 1-hour interval)
Number of subjects: 75
Study 34318912 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold therapy for 25 minutes, two times (at 1-hour interval)
Number of subjects: 75
Study 34318912 — intervention group
Group type: COMPARATOR
Intervention: Control group (no heat or cold therapy)
Number of subjects: 75
Study 32884241 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 90
Study 32884241 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 1.2 mg/kg
Number of subjects: 90
Study 32884241 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 90
Study 32884241 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control group S)
Number of subjects: 90
Study 35488192 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (0.35 µg/kg)
Number of subjects: 107
Study 35488192 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (3.5 µg/kg)
Number of subjects: 107
Study 34128721 — intervention group
Group type: EXPERIMENTAL
Intervention: DECTA with 300 mg of iodine per kilogram by using an optimized threshold
Number of subjects: 96
Study 34128721 — intervention group
Group type: COMPARATOR
Intervention: Conventional DECTA with 300 mg of iodine per kilogram using a conventional threshold
Number of subjects: 96
Study 34128721 — intervention group
Group type: COMPARATOR
Intervention: SECTA with standard iodine dose (600 mg of iodine per kilogram)
Number of subjects: 96
Study 32897369 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodophor
Number of subjects: 0
Study 32897369 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine
Number of subjects: 0
Study 34705101 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional Er: YAG laser plus Kligman's formula
Number of subjects: 20
Study 34705101 — intervention group
Group type: COMPARATOR
Intervention: Kligman's formula alone
Number of subjects: 20
Study 32216870 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia Care Mapping™ (DCM) intervention
Number of subjects: 726
Study 32216870 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 726
Study 35751421 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-field irradiation (EFI)
Number of subjects: 288
Study 35751421 — intervention group
Group type: COMPARATOR
Intervention: Pelvic radiotherapy (PRT)
Number of subjects: 288
Study 35751421 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-field irradiation (EFI) in CA9-only positive subgroup
Number of subjects: 288
Study 35751421 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-field irradiation (EFI) in CA9/HIFs double positive subgroup
Number of subjects: 288
Study 35751421 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA-seq analysis
Number of subjects: 288
Study 32862713 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring intervention (TI) group
Number of subjects: 450
Study 32862713 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) group
Number of subjects: 450
Study 37721178 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine diet (30 g glycine per 1 kg meat)
Number of subjects: 10
Study 37721178 — intervention group
Group type: COMPARATOR
Intervention: Control diet (horse meat only)
Number of subjects: 10
Study 34450475 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (25 mg/m2 every 3 weeks)
Number of subjects: 0
Study 34450475 — intervention group
Group type: COMPARATOR
Intervention: Abiraterone (1000 mg/day) or Enzalutamide (160 mg/day)
Number of subjects: 0
Study 34450475 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Number of subjects: 0
Study 34450475 — intervention group
Group type: COMPARATOR
Intervention: Abiraterone or Enzalutamide
Number of subjects: 0
Study 34450475 — intervention group
Group type: EXPERIMENTAL
Intervention: NLR (continuous covariate)
Number of subjects: 0
Study 33175279 — intervention group
Group type: EXPERIMENTAL
Intervention: Protaper Universal (PTU)
Number of subjects: 27
Study 33175279 — intervention group
Group type: COMPARATOR
Intervention: Hero Shaper (HS)
Number of subjects: 27
Study 33175279 — intervention group
Group type: COMPARATOR
Intervention: Hyflex CM (HCM)
Number of subjects: 27
Study 35620797 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers with insomnia symptoms
Number of subjects: 57
Study 34550084 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based integrated management program
Number of subjects: 231
Study 34550084 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 231
Study 32822246 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct helmet use with enforcement presence (camera or police personnel)
Number of subjects: 77932
Study 32822246 — intervention group
Group type: COMPARATOR
Intervention: Incorrect helmet use
Number of subjects: 77932
Study 32822246 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct helmet use
Number of subjects: 77932
Study 32822246 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of enforcement
Number of subjects: 77932
Study 33165503 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium Dose (MD) of the vaccine
Number of subjects: 742
Study 33165503 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dose (HD) of the vaccine
Number of subjects: 742
Study 33165503 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium Dose (MD) of the vaccine with 28 days interval
Number of subjects: 742
Study 33165503 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dose (HD) of the vaccine with 28 days interval
Number of subjects: 742
Study 33165503 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 742
Study 32689601 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic Rehabilitation group with VR (RRG+VR)
Number of subjects: 90
Study 32689601 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic Rehabilitation group without VR (RRG‐VR)
Number of subjects: 90
Study 32689601 — intervention group
Group type: COMPARATOR
Intervention: Conventional Rehabilitation group (CRG)
Number of subjects: 90
Study 34521604 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Usability Program
Number of subjects: 195
Study 34521604 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 195
Study 32922524 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac diethylamine 2.32% w/w gel, applied every 12 hours for 7 days before surgery
Number of subjects: 47
Study 32922524 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel, applied every 12 hours for 7 days before surgery
Number of subjects: 47
Study 35597980 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPTX-2 treatment (10 mg/kg intravenous infusions on Days 1, 3, and 5 in the first week of each 28-week cycle, then one infusion every 4 weeks up to Week 128)
Number of subjects: 111
Study 35597980 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPTX-2 treatment
Number of subjects: 111
Study 33647103 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction (phone ring and brief conversation during vignette)
Number of subjects: 88
Study 33647103 — intervention group
Group type: COMPARATOR
Intervention: Non-distracted (no distraction during vignette)
Number of subjects: 88
Study 33647103 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction (questions after distraction)
Number of subjects: 88
Study 33647103 — intervention group
Group type: COMPARATOR
Intervention: Non-distracted (questions after distraction)
Number of subjects: 88
Study 33060497 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot massage (3 sessions a week, 20 minutes each for 4 weeks)
Number of subjects: 0
Study 33060497 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34379701 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma free thiol levels at Day 1
Number of subjects: 217
Study 34379701 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma free thiol levels at Day 5
Number of subjects: 217
Study 34379701 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma free thiol levels at 30 minutes and 90 minutes
Number of subjects: 217
Study 33045376 — intervention group
Group type: EXPERIMENTAL
Intervention: Single triangle frontalis suspension using ePTFE suture
Number of subjects: 60
Study 33045376 — intervention group
Group type: COMPARATOR
Intervention: Fox pentagon frontalis suspension using ePTFE suture
Number of subjects: 60
Study 36335976 — intervention group
Group type: EXPERIMENTAL
Intervention: Fee for home delivery and monitoring of ART
Number of subjects: 162
Study 36335976 — intervention group
Group type: COMPARATOR
Intervention: Clinic-based ART (standard of care)
Number of subjects: 162
Study 33252440 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief counseling (inpatient counseling)
Number of subjects: 266
Study 33252440 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended counseling (brief counseling plus follow‐up counseling)
Number of subjects: 266
Study 33252440 — intervention group
Group type: COMPARATOR
Intervention: Control (no counseling)
Number of subjects: 266
Study 33252440 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended counseling
Number of subjects: 266
Study 33252440 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief counseling
Number of subjects: 266
Study 32371520 — intervention group
Group type: EXPERIMENTAL
Intervention: RECOVER model
Number of subjects: 890
Study 32371520 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 890
Study 36265942 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Paclitaxel-Coated Balloon (Ranger)
Number of subjects: 414
Study 36265942 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Paclitaxel-Coated Balloon (IN.PACT)
Number of subjects: 414
Study 33436658 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B Streptococcus (GBS) colonization in pregnant women
Number of subjects: 5621
Study 33436658 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive GBS infections in infants
Number of subjects: 5621
Study 33436658 — intervention group
Group type: EXPERIMENTAL
Intervention: Type III GBS in infants with invasive infections
Number of subjects: 5621